Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER) announced its participation in the BIO CEO & Investor Conference from February 14-17, 2022. The event will feature an on-demand recorded corporate presentation and virtual one-on-one meetings. Acer focuses on developing therapies for rare, life-threatening diseases with unmet medical needs. Its product pipeline includes ACER-001 for metabolic disorders, ACER-801 for induced vasomotor symptoms, EDSIVO™ for vascular Ehlers-Danlos syndrome, and ACER-2820 targeting infectious diseases like COVID-19.

NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually participate in the BIO CEO & Investor Conference on February 14-17, 2022.

Format:	On-demand recorded corporate presentation and one-on-one virtual meetings
Dates:	February 14-17, 2022
Presentation:	https://www.acertx.com/investor-relations/events-presentations/

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com

FAQ

What is the significance of Acer Therapeutics' participation in the BIO CEO & Investor Conference 2022?

Acer Therapeutics' participation in the BIO CEO & Investor Conference from February 14-17, 2022 demonstrates its commitment to investor engagement and highlights its innovative therapies for rare and serious diseases.

When is Acer Therapeutics presenting at the BIO CEO & Investor Conference?

Acer Therapeutics' presentation will take place virtually during the BIO CEO & Investor Conference from February 14-17, 2022.

What are the main products in Acer Therapeutics' pipeline?

Acer Therapeutics' pipeline includes ACER-001 for metabolic disorders, ACER-801 for induced vasomotor symptoms, EDSIVO™ for vascular Ehlers-Danlos syndrome, and ACER-2820 for infectious diseases like COVID-19.

Where can I find Acer Therapeutics' presentation from the BIO CEO & Investor Conference?

Acer Therapeutics' presentation can be accessed through their investor relations page at https://www.acertx.com/investor-relations/events-presentations/.

What type of company is Acer Therapeutics?

Acer Therapeutics is a pharmaceutical company focused on developing and commercializing therapies for serious rare and life-threatening diseases with significant unmet medical needs.